Table Of Content

Subject index of volume 25 (1998) \ 2{5-Carbomethox y-3B-(4-iodopheny!])nor Dual-detector single-photon emission to Absosrobrebde d Gdo se 565), Ve 629 trop' ane 19, 1666 mog:r aphy ' 1545 " rati techniau Carbon-!1 methionine 29, 1261 Dual-radionuclide scintigraphy 9 cceleravion tecnn ques » taIzZoOLlAaTmTiNdG e 16i3» 7 Carbon-14 2-deoxygé lucose 361 Dual-tracer autoradiography 361 5 124 Cardiac imaging 1308 DWAY 338 uteM ‘ UMi-s2chh.ee sm ic sLyonlad dreoowm e 5()9 ardiac neur.o nal function Dv; namic 575 ardiac phantom 1313 Dynamic antral scintigraphy 1293 ite myocardial infarction 1390 , : ardiac transplantation Dynamic intestine study 1531 denosine 394 ardiofocal collimators 3 Dynamic renal study 48 Adolescence 60! . ationic amino acids 20] AAdIsDoSr ptio1n4 of MacuV 13 ellular dosimetry: 2w0e5 i 14)4 Al, dose reductase inh, ibitor 1643 ‘rpebprdal blood eelfsl ow 1330 ECG-.g ated single-photon emission tomog FT 173 Alp! particle-emitting radionucli raphy 515 hallenge experiments 79 Echocardiography 69 11 709 hemical stability 793 EEG-video monitoring 166 mediastinum hemotactic peptide 34 Ejection fraction 1300 meenn hildren = /60 Emission computed tomography 1390 a nt tf holecystokinin 48] 1495 nolecy Kinin-b receptor Emission tomography 715 hromium-51 ethylene diamine tetra-acetic | pil “Ds) 166 wid 1630 Euthy. ro>i d g' oitre 1475 hronic, heart ffaaiilluurree Exercise rehabilitation talopran 19 External quality assurance 14] learance values 760 Extrapyramidal disorders 1270 NS lymphoma 1404 tile ' dence counting 167 lour Doppler sonography : 48 mparison | ymputed tomography 721, 1377 » modaliti: es ver of inknown origin 1442 Fluorine-18 fluoro-2-deoxyglucose 736 Fluorine-18 fluorodeoxyglucose 1238 1y<< %1 1479 15] Fluorine-18 fluorodeoxy VIUCOSE positron ‘Mission tomography g > < F |fluoro deoxy Fluorodeoxyglucose f-Met-Leu-Phe 347 Follicular thyroid carci I}FP-CIT 24 Functional conn Functional ne Fusion mag 18]fluoro G hvl-WAY- 100635 Gallium-67 scan Gamma « ametra Gamma amera 1 322 Gamma camera single-photon emission tomography 1524 Gamma imaging 607 Gamma probe 1489 Gamma-emitters 205 Gastric emptying 1293 Gastrin 424 Gastro-entero-pancreatic tract 1396 Gastroenteropancreatic tract tumours 639 Gastroenteropancreatic tumours 79 yndrome Gated magnetic resonance imaging 522 Subject index of volume 25 (1998) \ 2{5-Carbomethox y-3B-(4-iodopheny!])nor Dual-detector single-photon emission to Absosrobrebde d Gdo se 565), Ve 629 trop' ane 19, 1666 mog:r aphy ' 1545 " rati techniau Carbon-!1 methionine 29, 1261 Dual-radionuclide scintigraphy 9 cceleravion tecnn ques » taIzZoOLlAaTmTiNdG e 16i3» 7 Carbon-14 2-deoxygé lucose 361 Dual-tracer autoradiography 361 5 124 Cardiac imaging 1308 DWAY 338 uteM ‘ UMi-s2chh.ee sm ic sLyonlad dreoowm e 5()9 ardiac neur.o nal function Dv; namic 575 ardiac phantom 1313 Dynamic antral scintigraphy 1293 ite myocardial infarction 1390 , : ardiac transplantation Dynamic intestine study 1531 denosine 394 ardiofocal collimators 3 Dynamic renal study 48 Adolescence 60! . ationic amino acids 20] AAdIsDoSr ptio1n4 of MacuV 13 ellular dosimetry: 2w0e5 i 14)4 Al, dose reductase inh, ibitor 1643 ‘rpebprdal blood eelfsl ow 1330 ECG-.g ated single-photon emission tomog FT 173 Alp! particle-emitting radionucli raphy 515 hallenge experiments 79 Echocardiography 69 11 709 hemical stability 793 EEG-video monitoring 166 mediastinum hemotactic peptide 34 Ejection fraction 1300 meenn hildren = /60 Emission computed tomography 1390 a nt tf holecystokinin 48] 1495 nolecy Kinin-b receptor Emission tomography 715 hromium-51 ethylene diamine tetra-acetic | pil “Ds) 166 wid 1630 Euthy. ro>i d g' oitre 1475 hronic, heart ffaaiilluurree Exercise rehabilitation talopran 19 External quality assurance 14] learance values 760 Extrapyramidal disorders 1270 NS lymphoma 1404 tile ' dence counting 167 lour Doppler sonography : 48 mparison | ymputed tomography 721, 1377 » modaliti: es ver of inknown origin 1442 Fluorine-18 fluoro-2-deoxyglucose 736 Fluorine-18 fluorodeoxyglucose 1238 1y<< %1 1479 15] Fluorine-18 fluorodeoxy VIUCOSE positron ‘Mission tomography g > < F |fluoro deoxy Fluorodeoxyglucose f-Met-Leu-Phe 347 Follicular thyroid carci I}FP-CIT 24 Functional conn Functional ne Fusion mag 18]fluoro G hvl-WAY- 100635 Gallium-67 scan Gamma « ametra Gamma amera 1 322 Gamma camera single-photon emission tomography 1524 Gamma imaging 607 Gamma probe 1489 Gamma-emitters 205 Gastric emptying 1293 Gastrin 424 Gastro-entero-pancreatic tract 1396 Gastroenteropancreatic tract tumours 639 Gastroenteropancreatic tumours 79 yndrome Gated magnetic resonance imaging 522 Gated single-photon emission tomography lodine-123 iodoamphetamine 1637 Melanoma 1322, 1439, 1567 3, 522, 587 lodine-123-B-CIT 1270 Melanoma imaging agent 109 Gender-related differences 1293 lodine- 1 23-metaiodobenzylguanidine Metabolic and receptor imaging 1277 Geometric mean 115 1643 Metaiodobenzylguanidine 144, 229, 235 Gliomas 150, 1649 lodine-131 701 Metal chelating ligands 481 Global skeletal uptake 139 lodine-131 therapy 265, 1368 Metastases 1322 Glomerular filtration rate 1630 lodization of salt 367 L-[Methyl-''C]methionine 629 Glucose metabolism 559 L-3-[!-3]iodo-a-methyltyrosine 15 1 1B-Methoxy-17a-[!*3]iodovinyloestradiol Glutathione 793 lododoxorubicin 701 40 Graft function 1575 Irradiation effects 1423 2-methoxyisobutylisonitrile 714 Graves’ disease 367, 1475 Ischaemic cardiomyopathy 253 Microautoradiography 1423 Guidelines 1368 Ischaemic memory 1390 Minimal renal disease 760 Isolated limb perfusion 1567 MIRD method 629 H Iterative Bayesian reconstruction MIRD phantom 565 17° sa Iterative reconstruction 8 Mixed-ligand complexes 793 Head and neck cancer Monoamine oxidase B 464 Head and neck carcinoma 33 , K Monoclonal antibodies 471, 1489, 1562 Healthy female volunteer . \ Heart 167] Kidney depth 115 Monte Carlo simulation 1658 ea Motion artefact 1545 Hepatic functional reserve . Heeppaatti c resectat abilitI y 13») 77 L Motion correction 1524 Hepatobiliary imaging , 766 Language processing 15: 11 Multiple endocrine nzee oplasia 639 a ; ; lino a y oe Multiple myeloma 714 Heterogeneous labelling 1423 Lead chelates 47] ' <2 Multi-wire proportional counter 109 Hibernation 253 Left ventricular dysfunction 60 , a Te : i Myocardial blood flow 5] High linear energy transfer 1341 Left ventricular ejection fraction 515 Myo. cardif al glucose utilization ro7 36 S-HT,, receptors 338 Left ventricular function 522, 736 Myocardial imaging 1524 S-HT,, receptors 1617 Left ventricular hypertrophy 1308 197 Myocardial ischaemia 361 Human brain 19, 531 I eg: isiation a 8 Myo‘ cardial perfusion 3» , 23 94, 5c8o77, 1313 Hy: pertension 69 I e~ppttini n 60 ; 2 Myocardial scintigraphy 1643 Hyperthyroidism with intrinsic thyroid au I eucocyte scintigraphy 132 . . 7 : Myocardial single-photon emission tomog- tonomy 367 I iver transplantation 709 raphy 120, 1308 Hypothalamus 1666 I ow probability 271 Myocardial sympathetic function 229 Hypoxia 788, 1671 I ung cancer 1362 Myocardial uptake 1502 Lung neoplasm 1244 Myocardial viability 60 I ung ventilation 410 Myocardium 353, 594 51-‘ 5-I-ROI15‘0 16] . I ung9 volume e rere duction surgeser y 41 0 Ictal single-photon emission tomography I ymphocyte viability 1423 N 166 I ymphoma 729 " ane = I ymphoma staging 721 N2 disease 1495 Idiopathic dilated cardiomyopathy . Imaagge e ¢ contrast 497 : IL yysmipnhe osc2i0n]t igraphy 1489, 1567 NNeeco' kp lamsamssse s 5S5 493 1 Imaging 157,535 Neuroblastoma 144 Iminodiacetic analogues 766 M Neuroendocrine tumours 1277, 1396 Impaired consciousness 1330 antes tek? In vivo autoradiography 607 Magnetic resonance 1248 Noe-sseell coll laee corinne 14048 In vivo binding 31 Magnetic resonance imaging 166, 565 ay 4 dill ; Normal ranges 760 Indium-111 labelled platelet 247 Major depressive disorder 601 : Indium-111 octreotide scintigraphy 675 Malignancy grade 729 O Infection 132, 347,535, 1238 Malignant melanoma 1383 " Infection imaging 386 Malignant neoplasm 247 Ob protein 60 Inflammation 259. 503. 535 Mammary carcinoma 1248 Occlusiono f the unilateral portal vein In-octreotide 1482 Mammography 375, 491 Octapeptide 481 Insulin-dependent diabetes 503 Mathematical correlation 1531 Octreoscan 1482 Insulitis 503 Mathematical morphology 1300 Octreotide 182, 668 Integrins 1383 Maximum likelihood reconstruction 1658 Ordered subsets 215 Interleukin-1 32 4 7 Maximum likelihood-expectation maximi OrgOoa n anions 766 Internal radiation dosimetry zation 215 Ovarian cancer 1552 Inter-operator variability 55 MDR-! 401 Oxygen extraction fraction 1637 Interstitial pulmonary disease 2 Median root prior 215 Oxygen-15 labelled water 751 Intraperitoneal 1552 Mediastinal staging 1495 _ lodinated fatty acid 1390 Medical Exposure Directive 187 : lodine induced thyrotoxicosis 367 Medullary thyroid cancer 424 Paediatrics 115 lodine-123 101, 144, 1537 Medullary thyroid carcinoma 79,613,639, Paget's disease 101 lodine-123 , a@-methyl-L-tyrosine 177 1277, 1482 Pain palliation 1362 XVI . T Pancreas 259 Receptors 101, 687 Pancreatitis 259 Receptor-specific agents 535 #»™To(V)-DMSA 1277 Papillary thyroid carcinoma 695 Regional cerebral blood flow 157 Technetium-99m 132, 714, 793 Parkinson's disease 31] Regional wall motion 515 Technetium 99m diaminocyclohexane Pattern of uptake 714 Regions of interest 1531] 1630 In-DTPA-pb-Phe pentetreotide Registration 575 Technetium-99m furifosmin 1333 Pente treotide 1284 Reinjection at 4 hours 509 Technetium-99m galactosyl human serum Peptide receptor scintigraphy Renal transit time 48 albumin 1377 Peptides 101 201, 424 Renal transplantation 15 75 Technetium-99m hexamethylpropylene Perfusion 353, 594 Renal uptake 48, 201 386, 601, 1423 amine Oxime Peristalsis 1520 Renography 1520, 1575 Technetium-99m hexamethylpropylene eristaltic contractions 1531] Repeated treatment 1362 amine oxine 1330 *ristaltic waves 1531 Reperfusion 361 Technetium-99m HL91 361 ttrh idi1ne4 29 152)0 RRehveansicuuml-a!rIi8z8a tion61 3 594 Tech1n62e3t ium-99m macroaggregated albumin slycoprotein 401 Technetium 99m mercaptoacetyltriglycine otodynamic therapy Ss 55, 760 OPED 271 Salivary gland scintigraphy 128 Technetium-99m mercaptylacetyltriglycine inar imagin 19 Salivary glands 265 1575 sma Clearance rate Sarcoidosis 1284 Technetium-99m methoxyisobuty!tisonitrile sequestration Scatter 1232 375, 491 immer’s disease 367 scatter compensation 8 Technetium-99m pertechnetate 1448, olyneuropathy 709 Scatter correction 1658 1475 itron emission tomography RS 15 |15 7 cintigraphy 235, 594, 687, 709, 1284, Technetium-99m sestamibi 401,515 66. 338 559. 575. 729. 736 1383 1404, 1502, 1649 1248. 126] 14 9 Scintimammography 375, 491 Technetium-99m Technegas 1623 Self-dose 205 Technetium-99m tetrofosmin 522, 1333, eted radioimmunotherapy 1336 Sentinel node 1224, 1489, 1567, 1671 1448, 1502 tumour +3] Serotonin transporter 19, 1666 Technetium-99m-labelled anti-SSEA-| SIS 1429 Serum amyloid P component 701, 709 monoclonal antibody 386 landin Sestamibi single-photon emission tomogra Temporal lobe epilepsy 464 phy 69 Thallium chloride 126] Sheet line source 120 Thallium-201 120, 394, 594, 744, 1404 Simulation 1545 Thallium-201 scintigraphy 431 Simultaneous emission transmission 417 Phallium-201 single-photon emission to Simultaneous transmission-emission CT mography 60, 220, 509 uantification 41 an 153 Therapy scans 622 method Single-photon emission tomography 19 Thermoluminescent dosimeters 1435 40. 150. 157. 17 401 410, 464, Phree-dimensional imaging 410 4. 1261, 1270, 1330 1415 Chree-dimensional quantitative evaluation ibbit 60 1623. 1658 1623 .ac iclloopptr ide Small1 73 animal positron emission tomography Threshold 497 1diation Threshold technique 55 Small cell lung cancel Thrombocytopenia Somatostatin 668. 687 Thromboxane 265 o1ox Somatostatin analogues Thymus 622 idiation protection . Somatostatin receptor 1284 Thyroglobulin 695 hommmunoscintigrapl Somatostatin receptor scintigraphy 79, 675 Thyroid cancer 242 dioimmunotherapy } Somatostatin receptor subtypes 182 Thyroid carcinoma 687, 1368 tadioiodinated methylene Somatostatin receptors 1396 Thyroid stunning 1671 | i nMatA LO ; > SPI ] S Thyroid uptake 1475 Splenectomy 4 Thyrotoxicosis 1368 Squamous cell carcinoma 12 Thyroxine suppressive therapy 139 STA-MCA bypass Tomographic equilibrium gated blood pool Stnatum 531 scintigraphy 1300 Strontium-89 1362 Tracer kinetic modelling muciide Subacute thyroiditis 1448 Tracer kinetics 173 adionuclides Submandibular gland transplantation Transmission measurements 1435 adiopharn ace Surgical gamma probe 1224 ansmission scans 774 Survival 790 lriple energy window scatter correction 160 182 S-value 565 i537 activity in vivo and in vitro 192 Synthetic peptide 1383 Iriple-detector sins >-photon emission to Receptor targeted radionuclide therapy 008 Systolic thickening 515 mography 1545 Triple-energy-window scatter correction 120 V White blood cells 386 Tumor quantification 497 Whole-body cryosectioning 109 Vasoreactivity 1637 Tumor targeting 481 Vasospastic angina 229 Whole-body positron emission tomography Tumour differentiation 144 Vertebral metastases 635 417, 565, 629, 721 Tumour imaging 1567 Very low probability 271 Tumour recurrence 1649 Viable myocardium 744 xX Tumour uptake 1562 Vitamin B 1643 Tumour volume 1562 Xenon-133 gas 410 Tumours of the lung and of sympatho-adre- V Q scan X-ray computed tomography nal lineage 639 W Y U Washout 353 Watershed algorithm 1300 Yttrium-90 668 Urinary iodine excretion 1475 WAY-100635 173 Yttrium-90 biotin ape sh aaa A Bdows. ape P‘i€n y